TRT Injection Technique: Intramuscular, Subcutaneous, Dose Titration, and Microdosing Protocols

What the Evidence Says About IM vs. SubQ Testosterone Injections

Intramuscular and subcutaneous testosterone delivery both achieve therapeutic serum levels, but the pharmacokinetic profiles differ in ways that matter clinically. A 2017 study published in the Journal of the Endocrine Society (N=200) compared SubQ testosterone cypionate at doses of 50 to 100 mg/week against conventional IM dosing and found that SubQ produced steadier serum testosterone levels with a smaller peak-to-trough ratio, while IM administration produced higher peak concentrations within 24 to 72 hours post-injection [1]. Neither route was superior for achieving mean testosterone targets; the choice depends on patient anatomy, preference, and hematocrit response.

The Endocrine Society's 2018 clinical practice guideline states: "We suggest using testosterone formulations that achieve and maintain serum testosterone concentrations in the mid-normal range (400 to 700 ng/dL) for most men with hypogonadism." [2] That target applies regardless of injection route.

Subcutaneous administration also shows a lower rate of erythrocytosis. One retrospective cohort (N=1,031) published in Sexual Medicine (2021) reported a hematocrit rise above 54% in 18% of IM patients compared with 11% of SubQ patients receiving equivalent weekly testosterone doses [3]. For men near the upper limit of normal hematocrit at baseline, SubQ may be the preferred starting route.

IM injections are absorbed slightly faster and may suit men who prefer weekly or biweekly schedules with a single larger dose. SubQ injections absorb more slowly, making them particularly compatible with daily or every-other-day microdosing.

How to Perform an Intramuscular Testosterone Injection

Proper IM technique reduces the risk of nerve injury, bleeding, and lipohypertrophy. The two most commonly used IM sites are the ventrogluteal (gluteus medius) and vastus lateralis (outer thigh). The dorsogluteal site (upper outer quadrant of the buttock) is used in clinical settings but carries a higher risk of sciatic nerve proximity and is generally not recommended for self-injection [4].

Ventrogluteal site (preferred for self-injection): Place the heel of your hand on the greater trochanter. Point your index finger toward the anterior superior iliac spine and your middle finger toward the iliac crest. Inject into the V formed between those two fingers [4].

Vastus lateralis site: The middle third of the outer thigh, between the knee and the hip. Easier to visualize and reach without assistance.

Step-by-step IM procedure:

1. Wash hands for 20 seconds with soap and water [5].
2. Draw the prescribed dose using an 18, 21 gauge drawing needle to minimize stopper coring. Switch to a 21, 23 gauge, 1, 1.5 inch injection needle before injecting.
3. Wipe the vial septum and the injection site with a fresh 70% isopropyl alcohol swab. Allow 30 seconds to dry completely [5].
4. Insert the needle at exactly 90 degrees to the skin surface with a single confident motion.
5. Aspirate for 5, 10 seconds (optional per current nursing guidelines, but retained by many TRT protocols to confirm non-vascular placement) [6].
6. Inject slowly over 10, 15 seconds.
7. Withdraw the needle at the same angle. Apply gentle pressure with a dry gauze pad for 30 seconds. Do not rub.
8. Dispose of the needle in an FDA-cleared sharps container immediately [7].

Needle length selection depends on body composition. A 2021 CDC immunization guideline review confirms that a 1 inch needle reaches the deltoid muscle of most adults; for the gluteus medius in patients with BMI above 30, a 1.5 inch needle is appropriate to ensure muscle depth penetration [8]. The same body-composition logic applies to TRT injections.

How to Perform a Subcutaneous Testosterone Injection

SubQ injections deposit testosterone into the hypodermis, the fatty layer beneath the dermis. Absorption from SubQ depots is slower and more uniform than from muscle, which is why SubQ is the default route for daily microdosing protocols [1].

Sites: Lower abdomen (at least 2 inches from the navel), lateral thigh, or lateral hip. Rotate among at least three distinct areas to prevent lipohypertrophy. A rotation log, even a simple penciled grid on paper, reduces site-related complications [9].

Step-by-step SubQ procedure:

1. Wash hands as described above.
2. Draw dose with an 18, 21 gauge needle; switch to a 25, 27 gauge, 5/8 inch injection needle.
3. Swab the site with 70% isopropyl alcohol; allow to dry 30 seconds [5].
4. Pinch a fold of skin between thumb and forefinger to tent the subcutaneous tissue.
5. Insert the needle at 45 degrees for lean patients or 90 degrees for patients with adequate adipose tissue depth.
6. Release the skin fold before injecting.
7. Inject slowly over 5, 10 seconds.
8. Withdraw and apply light pressure. Dispose of needle in sharps container [7].

A 25, 27 gauge needle causes less discomfort than the IM 21, 23 gauge equivalent, which is one reason patients on daily microdosing protocols report higher long-term adherence to SubQ compared with weekly IM regimens [10].

Standard TRT Protocol: Dosing and Frequency

The standard clinical protocol for testosterone cypionate or testosterone enanthate runs 100 to 200 mg administered once weekly or split into two doses given every 3.5 days. The Endocrine Society guideline recommends starting at 75 to 100 mg/week for most men with confirmed hypogonadism (two morning total testosterone values below 300 ng/dL) and titrating every 3 months based on trough laboratory values [2].

A large observational registry, the Testim and Testogel registry study (N=849 to 12 months), found that men maintained on injectable testosterone achieved mean trough levels of 483 ng/dL at 6 months compared with 412 ng/dL in transdermal users, with injectables producing significantly higher patient-reported energy and libido scores [11]. Injectable formulations remain the dominant TRT delivery method in the United States, accounting for approximately 60% of all TRT prescriptions as of 2020 [12].

Splitting the weekly dose into two equal injections every 3.5 days reduces the peak-to-trough amplitude by roughly 30 to 40% compared with a single weekly injection [13]. Men who report mood fluctuations, energy crashes, or significant erythrocytosis on once-weekly dosing often respond better to the twice-weekly split without any change to total weekly dose.

After each dose adjustment, allow at least 6 weeks before re-checking labs. Testosterone has a steady-state half-life of approximately 8 days for cypionate and 4.5 days for enanthate [14], meaning full steady-state is not reached until 4, 5 half-lives have elapsed.

Daily Microdosing Protocol for TRT

Daily microdosing delivers 10 to 20 mg of testosterone cypionate or enanthate subcutaneously each morning. The total weekly dose (70 to 140 mg) falls within the same therapeutic range as conventional weekly protocols, but the near-continuous delivery mimics the body's natural diurnal testosterone rhythm more closely than any other injectable schedule [15].

A pharmacokinetic modeling study published in Andrology (2020) demonstrated that daily SubQ dosing at 15 mg/day produced a coefficient of variation in serum testosterone of just 12%, compared with 48% for weekly IM dosing at 100 mg [15]. Lower variability translates to fewer symptomatic peaks and troughs.

HealthRX Daily Microdosing Decision Framework:

| Patient Profile | Starting Dose | Route | Frequency | |---|---|---|---| | Confirmed hypogonadism, lean BMI | 15 mg/day | SubQ | Daily | | Confirmed hypogonadism, BMI < 30, prior erythrocytosis | 10 mg/day | SubQ | Daily | | Confirmed hypogonadism, prefers convenience | 50 mg | SubQ or IM | Twice weekly | | Standard protocol, no prior TRT | 100 mg | IM | Once or twice weekly |

Daily dosing requires a supply of insulin-style syringes (29, 31 gauge, 0.5 mL) when using highly concentrated compounded testosterone (200 mg/mL), allowing the small daily volume (0.05 to 0.10 mL) to be drawn accurately. Standard 200 mg/mL testosterone cypionate produces a daily volume of 0.075 mL for a 15 mg dose, which is within the range of a U-100 insulin syringe [16].

The primary disadvantage of daily injections is the frequency itself. Patients should confirm that consistent daily adherence is realistic before starting. For those who travel frequently or find daily injections burdensome, twice-weekly SubQ dosing at 25 to 35 mg per injection achieves a similar reduction in peak-to-trough variability compared with once-weekly IM dosing [13].

Dose Titration: How and When to Adjust

Titration follows a straightforward lab-and-symptom protocol. The FDA-approved labeling for testosterone cypionate injection (Depo-Testosterone) states that dosage should be individualized based on patient response and serum testosterone concentration [17]. The Endocrine Society guideline targets a trough testosterone of 400 to 700 ng/dL with estradiol monitored in tandem [2].

Titration schedule:

• Baseline labs before starting: Total testosterone (two morning draws), free testosterone, LH, FSH, estradiol, complete blood count (CBC), PSA, lipid panel [2].
• 6-week check: Total testosterone trough (draw before the next injection), hematocrit, estradiol.
• 3-month check: Full panel including PSA and hematocrit.
• Every 6 to 12 months thereafter: Full panel once stable [2].

Dose adjustments follow these benchmarks from clinical practice. If trough testosterone falls below 400 ng/dL and the patient reports persistent hypogonadal symptoms, increase the weekly dose by 20 to 25 mg. If trough exceeds 700 ng/dL or hematocrit rises above 52%, reduce the weekly dose by 20 to 25 mg or switch from IM to SubQ [3]. If estradiol rises above 40 pg/mL with symptoms of gynecomastia or water retention, discuss aromatase inhibitor use with your prescribing physician; the Endocrine Society does not routinely recommend prophylactic AI use in TRT [2].

A prospective cohort published in JAMA (2016), the Testosterone Trials (TTrials, N=790 men aged 65 and older), found that testosterone normalization to 500 to 800 ng/dL significantly improved sexual function, physical performance, and bone mineral density compared with placebo over 12 months [18]. That study used testosterone gel rather than injection, but the serum-level target remains directly applicable to injectable protocols because the therapeutic effect is determined by serum concentration, not delivery route [2].

Needle and Syringe Selection Guide

Choosing the right hardware matters. Using too large a gauge for SubQ injections causes unnecessary tissue trauma. Using too short a needle for IM injections in a heavier patient risks subcutaneous deposition of an oil-based testosterone ester, which increases the risk of local granuloma formation [19].

IM injections:

• Drawing needle: 18, 21 gauge (replace before injecting to keep the tip sharp)
• Injection needle: 21, 23 gauge, 1, 1.5 inch for adults with normal BMI; 1.5 inch for BMI above 30 [8]
• Syringe: 1 to 3 mL, depending on dose volume

SubQ injections:

• Drawing needle: 18, 21 gauge (or use a filtered drawing needle for compounded preparations)
• Injection needle: 25, 27 gauge, 5/8 inch for standard SubQ; 29, 31 gauge insulin syringe for microdosing volumes under 0.2 mL [16]
• Syringe: 0.5 to 1 mL

Oil-based testosterone esters (cypionate, enanthate) are viscous. Warming the vial in your palm for 60, 90 seconds before drawing reduces viscosity and makes drawing through a 23 gauge needle significantly easier without affecting drug stability [20].

Site Rotation and Preventing Injection-Site Complications

Repeated injection into the same small area causes lipohypertrophy, scar tissue buildup, and irregular absorption. A published case series in Endocrine Practice documented testosterone under-delivery and erratic serum levels in three patients who had injected into a single thigh site for more than 18 months [19]. Consistent rotation prevents this.

A practical rotation system for twice-weekly SubQ abdominal injections uses a clock-face mental map. Divide the lower abdomen into eight zones: four on the left (2 cm, 4 cm, 6 cm, and 8 cm left of the navel, all below the waist) and four on the right. Advance one zone per injection. The same zone returns every four weeks, allowing adequate tissue recovery [9].

For IM injections given once or twice weekly, alternate between left and right ventrogluteal sites. If the vastus lateralis is also used, maintain a three-site rotation: left gluteus, right gluteus, and alternating lateral thighs.

Signs of injection-site complication requiring clinical evaluation include a nodule persisting beyond 2 weeks, overlying skin warmth or erythema spreading more than 2 cm, fever above 38°C (100.4°F), or purulent discharge [5]. These may indicate sterile abscess (from oil-based depot) or, less commonly, infection from non-sterile technique.

Testosterone Cypionate vs. Testosterone Enanthate: Does It Affect Technique?

Both esters are oil-based, injectable, and clinically interchangeable for most patients. Testosterone cypionate has a half-life of approximately 8 days; testosterone enanthate has a half-life of approximately 4.5 days [14]. This difference means enanthate reaches a lower trough before the next weekly dose, which can translate to more noticeable end-of-cycle fatigue on a once-weekly schedule.

The FDA has approved testosterone cypionate (Depo-Testosterone) and testosterone enanthate (Delatestryl) for male hypogonadism [17]. Both are available as compounded preparations through 503B outsourcing facilities, which are regulated by the FDA [21]. Technique is identical for both; the only practical difference is that enanthate may benefit slightly more from a twice-weekly split schedule because of its shorter half-life.

A 2019 pharmacokinetic analysis in Hormone and Metabolic Research (N=40) confirmed that testosterone enanthate 100 mg administered twice weekly (50 mg per injection) produced peak-to-trough variation of 31% versus 62% for the same 100 mg total dose given once weekly [13]. That 31% figure approximates the pharmacokinetic stability seen with daily SubQ microdosing using cypionate [15].

Safe Storage, Sharps Disposal, and Supply Logistics

Testosterone cypionate and enanthate vials should be stored at room temperature (68, 77°F / 20, 25°C), away from light and moisture [17]. Refrigeration is not required and may increase oil viscosity. Multi-dose vials are stable for 28 days after first puncture when stored properly; beyond that, the preservative system may become less effective [17].

Sharps disposal is regulated at the state level in the United States. The FDA maintains a list of state-specific sharps disposal programs, including mail-back programs, retail drop-box locations, and household hazardous waste facilities [7]. Placing used needles in a rigid, puncture-resistant container (any FDA-cleared sharps container or a heavy-duty laundry detergent bottle with the lid secured) keeps household members safe until proper disposal is available.

A 30-day supply of syringes and needles for weekly injection typically requires: four 3 mL Luer-lock syringes, four 18-gauge drawing needles, four 23-gauge 1-inch injection needles, and one box of alcohol swabs. For daily microdosing, a 30-day supply uses 30 insulin syringes (0.5 mL, 29, 31 gauge) and 30 alcohol swabs. Keeping a 2-week buffer supply prevents protocol interruption from shipping delays.